China Medical System Holdings Limited
0867
주식 순위
#4685
Established in 1995 and headquartered in North Point, Hong Kong, China Medical... Established in 1995 and headquartered in North Point, Hong Kong, China Medical System Holdings Limited functions as an investment holding company with a primary focus on the development, marketing, and distribution of a wide array of pharmaceutical products throughout the People's Republic of China. The company's extensive portfolio addresses numerous therapeutic areas. Its cardiovascular offerings include Plendil for hypertension and stable angina, XinHuoSu for acute heart failure, and Imdur for coronary heart disease, chronic heart failure, and myocardial infarction prevention. For mental health and neurological support, it provides Deanxit to treat mild-to-moderate depression and anxiety, along with Parlodel tablets for endocrine and neuro system indications. Digestive and liver conditions are managed with products such as Ursofalk for gallstones and cholestatic liver disease, Salofalk for ulcerative colitis and Crohn's disease, Bioflor for diarrhea, Combizym for dyspepsia, and Ganfule capsules for primary liver cancer, plus MOVICOL for chronic constipation. The company also markets Augentropfen Stulln Mono eye drops for senile macula degeneration and asthenopia, Hirudoid for blunt trauma and superficial phlebitis, Elcatonin injection for osteoporosis, and Lamisil tablets for fungal infections. Respiratory issues are addressed by YiNuoShu, while infectious diseases benefit from DanShenTong capsules (for various infections like acne, tonsillitis, and boils) and YinlianQinggan granules for hepatitis. XiDaKang, a protein hydrolysate oral solution, is also part of its offerings. Beyond its pharmaceutical endeavors, the group is also actively involved in agriculture and livestock operations. China Medical System Holdings Limited operates as a subsidiary of Treasure Sea Limited.
주가
$1.33
시가총액
$3.23B
변동 (1일)
1.76%
변동 (1년)
-22.91%
국가
HK
거래 China Medical System Holdings Limited (0867)
카테고리
Healthcare
China Medical System Holdings Limited (0867)의 수익
Jun 2026 기준 수익 TTM: $309.11M
China Medical System Holdings Limited의 최신 재무 보고서에 따르면 회사의 현재 수익은 $309.11M입니다. 2023년에 회사는 $405.98M의 수익을 올렸으며 이는 2022년의 수익 $545.51M과 감소입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
China Medical System Holdings Limited의 수익 기록 (2006 ~ 2026)
연말 수익
| 연도 | 수익 | 변화 |
|---|---|---|
| 2026 (TTM) | $309.11M | 12.23% |
| 2024 | $275.42M | -32.16% |
| 2023 | $405.98M | -25.58% |
| 2022 | $545.51M | 0.31% |
| 2021 | $543.84M | 26.16% |
| 2020 | $431.08M | 20.66% |
| 2019 | $357.26M | 22.48% |
| 2018 | $291.68M | 4.94% |
| 2017 | $277.96M | 28.62% |
| 2016 | $216.11M | 31.88% |
| 2015 | $163.86M | -10.14% |
| 2014 | $182.36M | 64.80% |
| 2013 | $110.65M | 17.00% |
| 2012 | $94.57M | 39.34% |
| 2011 | $67.87M | 95.03% |
| 2010 | $34.80M | 29.24% |
| 2009 | $26.93M | 37.84% |
| 2008 | $19.54M | 88.74% |
| 2007 | $10.35M | 92.47% |
| 2006 | $5.38M | 0.00% |
유사 기업 또는 경쟁사의 수익
| 회사 | 수익 | 수익 차이 | 국가 |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 470.84% |
IN
|
